AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. KROS
  4. [8-K] Keros Therapeutics, Inc. Reports Material Event

[8-K] Keros Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source:

Stock KROS logo
Keros Therapeutics, Inc.

NASDAQ:KROS

KROS Rankings

#4229 Ranked by Market Cap
N/A Ranked by Dividends

KROS Latest News

Aug 6, 2025
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
Aug 6, 2025
Keros Therapeutics Reports Second Quarter 2025 Financial Results
Jul 17, 2025
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
Jun 9, 2025
ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal
Jun 9, 2025
Keros Announces Return of $375 Million in Excess Capital to Stockholders

KROS Latest SEC Filings

Aug 6, 2025
[8-K] Keros Therapeutics, Inc. Reports Material Event
Aug 6, 2025
[10-Q] Keros Therapeutics, Inc. Quarterly Earnings Report
Aug 6, 2025
[8-K] Keros Therapeutics, Inc. Reports Material Event
Jul 15, 2025
[8-K] Keros Therapeutics, Inc. Reports Material Event
Jun 24, 2025
[Form 4] Keros Therapeutics, Inc. Insider Trading Activity

KROS Stock Data

585.27M
38.64M
2.31%
110.12%
12.43%
Biotechnology
Pharmaceutical Preparations
United States
LEXINGTON